Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Chlamydia trachomatis | oxoacyl-ACP synthase III | 0.2501 | 0.6346 | 0.5 |
Schistosoma mansoni | tyrosine kinase | 0.1778 | 0.3217 | 0.3117 |
Schistosoma mansoni | tyrosine kinase | 0.1778 | 0.3217 | 0.3117 |
Echinococcus multilocularis | insulin receptor | 0.1069 | 0.0145 | 0.0145 |
Schistosoma mansoni | tyrosine kinase | 0.1778 | 0.3217 | 0.3117 |
Schistosoma mansoni | tyrosine kinase | 0.1797 | 0.3299 | 0.32 |
Echinococcus multilocularis | epidermal growth factor receptor | 0.3345 | 1 | 1 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.2501 | 0.6346 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.2501 | 0.6346 | 0.5 |
Echinococcus granulosus | melanoma receptor tyrosine protein kinase | 0.1797 | 0.3299 | 0.32 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.2501 | 0.6346 | 0.5 |
Echinococcus granulosus | epidermal growth factor receptor | 0.3345 | 1 | 1 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.2501 | 0.6346 | 0.5 |
Loa Loa (eye worm) | TK/EGFR protein kinase | 0.3345 | 1 | 1 |
Echinococcus multilocularis | insulin growth factor 1 receptor beta | 0.1069 | 0.0145 | 0.0145 |
Schistosoma mansoni | tyrosine kinase | 0.1797 | 0.3299 | 0.32 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.2501 | 0.6346 | 0.5 |
Echinococcus granulosus | epidermal growth factor receptor | 0.1797 | 0.3299 | 0.32 |
Echinococcus multilocularis | epidermal growth factor receptor | 0.1797 | 0.3299 | 0.3299 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.2501 | 0.6346 | 0.5 |
Schistosoma mansoni | tyrosine kinase | 0.3345 | 1 | 1 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.2501 | 0.6346 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.